KRAS G12D protein screening for pancreatic cancer clinical trials using an AlGaN/GaN high electron mobility transistor biosensor
Authors
Sheng-Ting Hung
Cheng Yan Lee
Chen-Yu Lien
Cheng-Hsuan Chan
Ya-Han Yang
Quark Yungsung Chen
Kuang-Hung Cheng
Kung-Kai Kuo
Li-Wei Tu
Ching-Wen Chang
Abstract
Clinical trials screening KRAS G12D protein for 30 pancreatic ductal adenocarcinoma (PDAC) patients and 30 healthy donors were conducted utilizing an AlGaN/GaN high electron mobility transistor (HEMT) biosensor. All resistance change ratios of PDAC patients are higher than the standard deviation above the mean resistance change ratio obtained from all healthy donors. The results demonstrate the effectiveness of the HEMT biosensor and reveal its potential for early detection of pancreatic cancer with KRAS G12D protein screening.
